Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas(Global Viral), Kathrin U. Jansen(Pfizer (United States)), Paul Liberator(Pfizer (United States)), Nicholas Kitchin(Johns Hopkins University), Satrajit Roychoudhury(Novartis (United States)), Kenneth Koury(Johns Hopkins University), Xia Xu(Pfizer (United States)), Kena A. Swanson(Pfizer (United States)), John L. Perez(AstraZeneca (France)), Robert W. Frenck(Naval Medical Research Command), Stephen Lockhart(Johns Hopkins University), Edson Duarte Moreira(Institute of Rural Management Anand), Philip R. Dormitzer(Boston Children's Hospital), Dina B Tresnan(Johns Hopkins University), Susan Mather(Johns Hopkins University), Qi Yang(Hainan University), Alejandra Gurtman(Johns Hopkins University), Warren V. Kalina(Pfizer (United States)), Haylene Nell(Johns Hopkins University), Salim Bouguermouh(Pfizer (United States)), Uğur Şahin(Johannes Gutenberg University Mainz), William C. Gruber(Pfizer (United States)), Judith Absalon(GlaxoSmithKline (United States)), Serhat Ünal(Hacettepe University), Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), David Cooper(Johns Hopkins University), Ruth Bailey(Johns Hopkins University), Laura L Hammitt(Johns Hopkins University), Gonzalo Pérez Marc(Johns Hopkins University), Özlem Türeci(Johannes Gutenberg University Mainz), Axel Schaefer(Johns Hopkins University), Fernando P. Polack(Johns Hopkins University)
Cited by 144
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k